Abstract 1343
Background
Inhibition of vascular endothelial growth factor (VEGF) has shown antiangiogenic effects and immunomodulatory effects through enhancing tumor infiltration of immune cells in advanced renal cell carcinoma (RCC). Combination of checkpoint inhibitors with targeted therapy has synergistic antitumor activities and recent studies have demonstrated survival benefits. Yet, there are notable safety concerns. We conducted a systematic review and meta-analysis of randomized controlled trials (RCT) to determine the risk of treatment-related adverse events (TRAE) and treatment discontinuation due to TRAE.
Methods
PUBMED, MEDLINE, EMBASE databases and meeting abstracts from inception through March 2019 were queried. RCTs utilizing upfront checkpoint inhibitors combination therapy in patients with advanced RCC were incorporated. The primary meta- analytic approach was a random effects model using the Mantel-Haenszel (MH) method. It was used to calculate the estimated pooled risk ratio (RR) with 95% confidence interval (CI).
Results
4 phase III RCTs including 3758 patients with advanced RCC were eligible. The study arm used nivolumab+ ipilimumab, pembrolizumab+ axitinib, avelumab+ axitinib or atezolizumab+ bevacizumab while control arm utilized sunitinib. The randomization ratio was 1:1 in all studies. The pooled RR of any-grade TRAE was significant at 0.97 (95% CI: 0.95 –0.99, P = 0.007) and RR of high-grade TRAE was 0.88 (95% CI: 0.72 –1.09, P = 0.24). Treatment discontinuation due to TRAE was reported in 314 (16.84%) vs 200 (10.75%) in control group with RR of 1.43 (95% CI: 0.79 –2.57, P = 0.23). Treatment-related deaths were noted in 20 (1.07%) in study arm vs 13 (0.70%) in control arm. The pooled RR was not significant at 1.57 (95% CI: 0.62 –4.01, P = 0.34).
Conclusions
The risk of developing any-grade TRAE was reduced in upfront checkpoint inhibitors combination arm compared to standard sunitinib group, favoring combination therapy. Moreover, no increase in the risk of treatment related deaths as well treatment discontinuation due to TRAE was noted in the study arm.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Kyaw Zin Thein.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5822 - Greek nursing students experience facing death in clinical practice
Presenter: Maria Dimoula
Session: Poster Display session 3
Resources:
Abstract
2866 - HOPEVOL: Hospice care appropriate to the wishes and needs of patients in the palliative terminal phase.
Presenter: Merel van Klinken
Session: Poster Display session 3
Resources:
Abstract
829 - Mindfulness-based stress reduction in early palliative care for advanced cancer patients : an italian single-centre study. MINDEEP
Presenter: Emilia Gianotti
Session: Poster Display session 3
Resources:
Abstract
2702 - Optimising Inpatient Oncology Care
Presenter: Lisa Judge
Session: Poster Display session 3
Resources:
Abstract
1527 - Analysis on the Implementation Results of Family Sickbed for Oncology Patients in Dongshi Township Health Centers from 2015 to 2017
Presenter: Yayu Huang
Session: Poster Display session 3
Resources:
Abstract
2054 - Exploring needs for palliative care and quality of life for oncology patients with advanced disease who undergo radiotherapy
Presenter: Foteini Antonopoulou
Session: Poster Display session 3
Resources:
Abstract
5605 - Cytotoxic contamination in cancer care settings – Risks and safety awareness among cancer nurses
Presenter: Sandra Lundman Vikberg
Session: Poster Display session 3
Resources:
Abstract
5769 - Understanding Chemotherapy - group education sessions prior to commencing chemotherapy
Presenter: Aileen McHale
Session: Poster Display session 3
Resources:
Abstract
2620 - Estimation of HPQ-based absenteeism and presenteeism in cancer patients via ResearchKit
Presenter: Shunsuke Kondo
Session: Poster Display session 3
Resources:
Abstract
4705 - Identifying falls-related variables and risk factors in hospitalised cancer patients
Presenter: Maria Montserrat Martí Dillet
Session: Poster Display session 3
Resources:
Abstract